Helix BioPharma Corp. (TSX: “HBP”) (OTC PINK: HBPCD) (FRANKFURT: HBP0) (“Helix” or the “Company”), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology, based on its proprietary technological platform DOS47, today announces that it has commenced trading on the Frankfurt Boerse under the following:
Trading symbol: HBP0
WKN: A40GN1
ISIN: CA4229102088